Max Jan

5.4k total citations · 3 hit papers
28 papers, 2.9k citations indexed

About

Max Jan is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Max Jan has authored 28 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 12 papers in Hematology. Recurrent topics in Max Jan's work include CAR-T cell therapy research (12 papers), Acute Myeloid Leukemia Research (8 papers) and Protein Degradation and Inhibitors (8 papers). Max Jan is often cited by papers focused on CAR-T cell therapy research (12 papers), Acute Myeloid Leukemia Research (8 papers) and Protein Degradation and Inhibitors (8 papers). Max Jan collaborates with scholars based in United States, Spain and United Kingdom. Max Jan's co-authors include Ravindra Majeti, Irving L. Weissman, Ash A. Alizadeh, Mark P. Chao, Stephen R. Quake, Thomas M. Snyder, Paresh Vyas, Feifei Zhao, Chad Tang and M. Ryan Corces and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Max Jan

27 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

2010 845 citations Mark P. Chao, Ash A. Alizadeh et al. Cell profile →
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

2012 522 citations Max Jan, Irving L. Weissman et al. Science Translational Medicine profile →
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

2022 225 citations Rebecca C. Larson, Michael C. Kann et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Max Jan United States	14	1.4k	1.1k	1.0k	724	287	28	2.9k
Armin Ehninger Germany	25	659 0.5×	1.3k 1.2×	925 0.9×	495 0.7×	89 0.3×	42	2.4k
Kristin J. Hope Canada	17	573 0.4×	1.1k 1.0×	1.6k 1.6×	1.2k 1.6×	74 0.3×	38	2.9k
Fabiana Perna United States	20	643 0.5×	1.5k 1.3×	1.3k 1.3×	446 0.6×	59 0.2×	62	2.7k
Jana Krošl Canada	24	430 0.3×	435 0.4×	1.3k 1.3×	777 1.1×	128 0.4×	38	2.1k
Richard W.J. Groen Netherlands	28	830 0.6×	1.6k 1.4×	1.3k 1.3×	1.5k 2.1×	36 0.1×	69	3.0k
Armando G. Poeppl Canada	7	475 0.3×	534 0.5×	951 0.9×	922 1.3×	105 0.4×	10	1.9k
David Flowers United States	20	524 0.4×	933 0.8×	1.7k 1.7×	988 1.4×	68 0.2×	43	3.2k
Kalindi Parmar United States	28	321 0.2×	862 0.8×	2.1k 2.1×	706 1.0×	138 0.5×	60	3.0k
Claudia S. Huettner United States	24	933 0.7×	714 0.6×	1.5k 1.5×	1.5k 2.1×	87 0.3×	44	3.3k
Jared K. Burks United States	28	677 0.5×	905 0.8×	1.3k 1.3×	356 0.5×	32 0.1×	85	2.5k

Countries citing papers authored by Max Jan

Since Specialization

Citations

This map shows the geographic impact of Max Jan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Jan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Jan more than expected).

Fields of papers citing papers by Max Jan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Jan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Jan. The network helps show where Max Jan may publish in the future.

Co-authorship network of co-authors of Max Jan

This figure shows the co-authorship network connecting the top 25 collaborators of Max Jan. A scholar is included among the top collaborators of Max Jan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Jan. Max Jan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sreekanth, Vedagopuram, Max Jan, Kevin T. Zhao, et al.. (2025). A Molecular Glue Approach to Control the Half-Life of CRISPR-Based Technologies. Journal of the American Chemical Society. 147(27). 23844–23856. 3 indexed citations

Kembuan, Gabriele, et al.. (2024). Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends in cancer. 10(4). 312–331. 13 indexed citations

Nguyen, Tuan M., Vedagopuram Sreekanth, Arghya Deb, et al.. (2023). Proteolysis-targeting chimeras with reduced off-targets. Nature Chemistry. 16(2). 218–228. 67 indexed citations

Kann, Michael C., Emily M. Schneider, Amanda A. Bouffard, et al.. (2023). Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7. Leukemia. 38(3). 590–600. 4 indexed citations

Kembuan, Gabriele, Michael C. Kann, William M. Lin, et al.. (2023). Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell chemical biology. 31(2). 338–348.e5. 7 indexed citations

Lin, William M., Nelson H. Knudsen, Amanda A. Bouffard, et al.. (2023). A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy. Blood. 142(Supplement 1). 4825–4825.

Larson, Rebecca C., Michael C. Kann, Stefanie R. Bailey, et al.. (2022). CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 604(7906). 563–570. 225 indexed citations breakdown →

Leick, Mark B., Harrison Silva, Irene Scarfò, et al.. (2022). Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 40(5). 494–508.e5. 88 indexed citations

Wehrli, Marc, Rebecca Larson, Irene Scarfò, et al.. (2022). Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). Cancer Research. 82(12_Supplement). 569–569. 1 indexed citations

10.

Jan, Max, Xinyan Lu, Mikołaj Słabicki, et al.. (2022). Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion Degron. ACS Chemical Biology. 17(1). 24–31. 6 indexed citations

11.

Jan, Max, Irene Scarfò, Rebecca C. Larson, et al.. (2021). Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Science Translational Medicine. 13(575). 180 indexed citations

12.

Jan, Max, Adam S. Sperling, & Benjamin L. Ebert. (2021). Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide. Nature Reviews Clinical Oncology. 18(7). 401–417. 91 indexed citations

13.

Miller, Peter G., Adam S. Sperling, Elliott J. Brea, et al.. (2021). Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances. 5(15). 2982–2986. 67 indexed citations

14.

Jan, Max, Julian A. Villalba, Paola Dal Cin, et al.. (2020). A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Advances. 4(3). 445–448. 9 indexed citations

15.

Jan, Max, Benjamin L. Ebert, & Siddhartha Jaiswal. (2016). Clonal hematopoiesis. Seminars in Hematology. 54(1). 43–50. 74 indexed citations

16.

Davis, Jessica L., et al.. (2015). Development and validation of an app-based cell counter for use in the clinical laboratory setting. Journal of Pathology Informatics. 6(1). 2–2. 5 indexed citations

17.

Chung, Stephen S., Wendy W. Pang, Gino K. In, et al.. (2012). CD99 Identifies Disease Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes. Blood. 120(21). 210–210. 2 indexed citations

18.

Rizki, Gizem, Terri Iwata, Christian G. Riedel, et al.. (2011). The Evolutionarily Conserved Longevity Determinants HCF-1 and SIR-2.1/SIRT1 Collaborate to Regulate DAF-16/FOXO. PLoS Genetics. 7(9). e1002235–e1002235. 87 indexed citations

19.

Chao, Mark P., Ash A. Alizadeh, Chad Tang, et al.. (2010). Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. Cancer Research. 71(4). 1374–1384. 294 indexed citations

20.

Chao, Mark P., Ash A. Alizadeh, Chad Tang, et al.. (2010). Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. Cell. 142(5). 699–713. 845 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact